Last reviewed · How we verify
Orlistat 60
At a glance
| Generic name | Orlistat 60 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial With EMP16 in Preparation for Late Phase Studies (PHASE2)
- Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia (PHASE2)
- Anti-obesity Effects of Dandelion (Taraxacum Officinale L.) (NA)
- Study Exploring the Supportive Effect of Acarbose in Weight Management (PHASE2)
- Orlistat for the Treatment of Type I Hyperlipoproteinemia (PHASE2)
- A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary) (PHASE1, PHASE2)
- Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg (NA)
- Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Orlistat 60 CI brief — competitive landscape report
- Orlistat 60 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI